Current News - U.S.
- Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
- Study shows once-daily, extended-release formulation of nevirapine was not inferior to twice-daily VIRAMUNE in treatment-naïve HIV-1 infected patients
- Boehringer Ingelheim announces pivotal phase III data showing linagliptin reduced blood sugar compared to placebo in people with type 2 diabetes
- Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting
- Key Facts on HSDD and Flibanserin
- New Game on Facebook Helps People with Diabetes Improve Everyday Behaviors
- Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al in Lancet Oncology June 2010
- DRIVE4COPD Makes Its Mark on American Health
- Zantac Teams with Travel Channel for “Beat the Heat” Tour
- Boehringer Ingelheim to present new data regarding its investigational compound BIBW 2992 in head and neck cancer and non-small cell lung cancer
- View more Current News : : View the News Archive
BI Spotlight
Boehringer Ingelheim Annual Press Conference 2010
April 20, 2010 
Boehringer Ingelheim presents its 2009 business results and the outlook for 2010 at the Annual Press Conference in Ingelheim, Germany.
Product Sites
Job Openings
Patient Assistance Program
R&D
